Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) on Friday announced positive results from the Phase 3b SPECTREM study, demonstrating the efficacy of TREMFYA (guselkumab) in treating low body surface area (BSA) moderate plaque psoriasis with special site involvement.

Sensitive or highly visible areas affected by plaque psoriasis, including the scalp, face, skin folds and genitals, are considered "special sites" and can have significant impact on patients' daily lives.

The study found that TREMFYA significantly improved skin clearance and quality of life for patients with this often overlooked condition.

A significantly greater proportion of patients who received TREMFYA achieved the primary endpoint of an Investigator's Global Assessment (IGA) score of cleared (0) or minimal disease (1) compared to those who received placebo (74.2% versus 12.4%, respectively).

This groundbreaking research highlights the potential of TREMFYA to benefit a broader range of psoriasis patients, including those with smaller affected areas.